Lv63
2090 积分 2022-06-18 加入
Treatment of Elderly Patients with Overactive Bladder: Has Mirabegron Come of Age?
9天前
已完结
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men
9天前
已完结
European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence
9天前
已完结
Women with overactive bladder should be referred to urogynaecology
10天前
已完结
Overactive bladder in women
10天前
已完结
Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
22天前
已完结
Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data
23天前
已完结
Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
24天前
已完结
Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing’s disease
1个月前
已完结
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
1个月前
已完结
皖公网安备34019202002308
